Stratec SE · XETR:SBS

Stratec — Investor Presentation (January 2016)

31 slides from Stratec's investor presentation, January 2016

  1. Slide 1: IR Company Presentation

    IR Company Presentation January 2016

  2. Slide 2: Safe Harbor Statement

    SAFE HARBOR STATEMENT Forward-looking statements involve risks. This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realis

  3. Slide 3: Agenda

    AGENDA  OVERVIEW AND BUSINESS MODEL  THE IVD MARKET  FINANCIALS  FUTURE GROWTH IR Company Presentation - www.stratec.com 3 January 2016

  4. Slide 4: Overview and Business Model

    OVERVIEW AND BUSINESS MODEL IR Company Presentation - www.stratec.com 4 January 2016

  5. Slide 5: STRATEC at a Glance

    Overview & Business Model The IVD Market Financials Future Growth STRATEC AT A GLANCE Market leader in automation solutions for the diagnostics industry Listed on TecDAX (Deutsche Boerse) 550 employees worldwide More than 12,000 systems installed globally Revenue € 144.9 million in 2014 Revenue and

  6. Slide 6: Investment Snapshot

    Overview & Business Model The IVD Market Financials Future Growth INVESTMENT SNAPSHOT • Market leader in automation solutions in the diagnostic industry • Broad installed base of more than 12,000 systems across over 20 system families including: - Siemens’ ADVIA Centaur - DiaSorin’s LIAISON XL - Hol

  7. Slide 7: Unique Market Position: STRATEC in the IVD Value Chain

    Overview & Business Model The IVD Market Financials Future Growth UNIQUE MARKET POSITION STRATEC IN THE IVD VALUE CHAIN Diagnostic Blood Banks, Patients Companies Laboratories STRATEC develops Partners market Laboratories Growth drivers: and manufactures systems together performing tests • Aging pop

  8. Slide 8: Business Model

    Overview & Business Model The IVD Market Financials Future Growth BUSINESS MODEL STRATEC provides instrumentation, software and automation solutions – OEM development and manufacturing – More than 2,700 fully automated analyzer systems manufactured in 2014 – Wide range of intellectual property right

  9. Slide 9: Securing Return on Investment

    Overview & Business Model The IVD Market Financials Future Growth SECURING RETURN ON INVESTMENT Long-term agreements with partners – Milestone payments during development stage – Operating sales during series production stage – Continuous revenues from consumable sales Minimum volume commitment – Fi

  10. Slide 10: The IVD Market

    THE IVD MARKET IR Company Presentation - www.stratec.com 10 January 2016

  11. Slide 11: IVD Market Segments

    IVD MARKET SEGMENTS / IVD Market: ~ 50 billion USD in 2015 Market by product type Market by sector CAGR 2013 – 2018: IVD Market: 4% Reagents / Chemistry Molecular Diagnostic: 8% 80% Instrument Services Clinical Chemistry Immunodiagnostic: 4% Instrumentation 17% Immunodiagnostic Hematology: 2 % Micro

  12. Slide 12: Outsourced vs In-House Instrumentation Market

    Overview & Business Model The IVD Market Financials Future Growth OUTSOUCED VS IN HOUSE INSTRUMENTATION MARKET 2010 2015 2020 Total Outsourced Outsourced Outsourced 27 % 36 % 44 % instrumentation ~ 7.5 billion USD Source: Own estimates based on In House In House In House historical market data and r

  13. Slide 13: Benefits of Outsourcing

    Overview & Business Model The IVD Market Financials Future Growth BENEFITS OF OUTSOURCING PLANNING & LOWER INNOVATION EFFICIENCY SPEED COST OF EXECUTION OWNERSHIP STRATEC  Highly specialized team  Complex project management  Constant innovation through ongoing  Cost and budget in line developmen

  14. Slide 14: Global Top 20 IVD Companies

    Overview & Business Model The IVD Market Financials Future Growth GLOBAL TOP 20 – IVD COMPANIES Revenues 2014 (USD billion) 1. Roche Diagnostics 8.9 2. Danaher 5.0 Customer STRATEC Instrumentation 3. SIEMENS 4.8 4. Abbott Diagnostics 4.7 5. Thermo Fisher 3.3 Customer STRATEC Data Management 6. Alere

  15. Slide 15: Financials

    FINANCIALS IR Company Presentation - www.stratec.com 15 January 2016

  16. Slide 16: Financials at a Glance

    Overview & Business Model The IVD Market Financials Future Growth FINANCIALS AT A GLANCE Key figures after the first nine months (€ million) September 30, 2015 September 30, 2014 Change Sales 107.2 105.3 + 1.8% EBIT 19.2 17.7* + 8.8% EBIT margin (%) 17.9 16.8* + 110 bps Consolidated net income 15.9

  17. Slide 17: Sales, EBIT and EBIT Margin

    Overview & Business Model The IVD Market Financials Future Growth SALES EBIT & EBIT MARGIN 9-Months Sales compared to Annual Sales 9-Months EBIT compared to Annual EBIT 160 144.9 EBIT in € million EBIT margin in % 140 128.0 116.6 122.4 26 24.1 22% 120 24 21.8 21% 22 20% 100 19.5 € million 20 17.6 19

  18. Slide 18: Installed Base & Product Groups

    Overview & Business Model The IVD Market Financials Future Growth INSTALLED BASE & PRODUCT GROUPS As of December 31 As of December 31 Delivered systems & installed base Relative share by product group 14.000 100% 12.000 90% 80% 10.000 70% 8.000 60% 50% 6.000 40% 4.000 30% 20% 2.000 10% 0 0% 2010 201

  19. Slide 19: Earnings After Nine Months

    Overview & Business Model The IVD Market Financials Future Growth EARNINGS AFTER NINE MONTHS 9-Months EPS compared to Annual EPS 1,80 1.71 1,60 • 9M tax rate at 18.1% (9M/2014: 16.4%) 1,40 1.32 1.32 • Dividend continuity expected, subject 1,20 1.06 to financing growth EUR 1,00 • EPS after nine month

  20. Slide 20: Cash Flow

    Overview & Business Model The IVD Market Financials Future Growth CASH FLOW As of September 30 IFRS (€ million) 9M/2015 9M/2014 Cash flow 17.8 19.5 Cash flow – operating activities 21.5 25.7 Cash flow – investing activities -5.3 -5.7 Cash flow – financing activities -8.7 -7.9 Free cash flow 16.1 20.

  21. Slide 21: Future Growth

    FUTURE GROWTH IR Company Presentation - www.stratec.com 21 January 2016

  22. Slide 22: Focus in 2016

    Overview & Business Model The IVD Market Financials Future Growth FOCUS IN 2016 REVENUE BUSINESS PROFITABILITY AND GROWTH DEVELOPMENT CASH FLOW  New product launches and ramp-ups  Extension of development and  Improve structure for  Established products in new markets manufacturing capacities ma

  23. Slide 23: Sales Guidance

    Overview & Business Model The IVD Market Financials Future Growth SALES GUIDANCE Sales Guidance until 2017: • 2014 to 2017: 8% - 12% CAGR based on 2013 250 CAGR 4-year sales 2014 - 2017: 8% - 12% based on 2013 2015 200 2013 Sales: € 128 million • Slight sales growth / similar as reported € million i

  24. Slide 24: Contact

    CONTACT STRATEC Biomedical AG TICKER Gewerbestr. 37 Symbol: SBS.DE 75217 Birkenfeld Bloomberg: SBS:GR Germany Reuters: SBSG.DE Tel: +49 7082 7916-0 ISIN: DE000STRA555 Fax: +49 7082 7916-999 www.stratec.com WKN: STRA55 Marcus Wolfinger CEO m.wolfinger@stratec.com THANK YOU FOR YOUR ATTENTION! IR Comp

  25. Slide 25: Appendix

    stratecee biomedical APPENDIX

  26. Slide 26: STRATEC Group

    STRATEC GROUP IR Company Presentation - www.stratec.com A1 January 2016

  27. Slide 27: Key Figures at a Glance

    KEY FIGURES AT A GLANCE AS OF DECEMBER 31 IFRS (€ million) 2010 2011 2012 2013 2014 Sales 102.0 116.6 122.7 128.0 144.9 EBIT 17.6 21.8 15.6 19.5 24.1 EBIT margin (%) 17.3 18.7 12.7 15.2 16.6 Consolidated net income 13.0 15.3 12.5 15.5 19.8 Earnings per share (€) 1.14 1.32 1.06 1.32 1.71 Dividend per

  28. Slide 28: Shareholder Structure & Share

    SHAREHOLDER STRUCTURE & SHARE SHAREHOLDER STRUCTURE (as of: 09/30/2015) Fixed and family ownership (incl. investment companies) Treasury shares ~ 18.2% Institutional investors ~ 41.7% Retail investors incl. not identified institutional investors ~ 40.0% SHARE ~ 0.1% IPO Aug. 1998 Capital increase <

  29. Slide 29: Institutional Shareholders Top 15

    INSTITUTIONAL SHAREHOLDERS TOP 15 AS OF SEPTEMBER 2015 Holder Name Holding Allianz Global Investors Europe, GER 7.1 % Threadneedle Asset Management, GBR 5.0 % Montanaro Asset Management, GBR 4.8 % OppenheimerFunds, USA 3.0 % Financiere de l‘Echiquier, FRA 2.9 % BNP Paribas Investment Partners Belgiu

  30. Slide 30: Analyst Coverage

    ANALYST COVERAGE Berenberg Bank Bryan, Garnier & Co Dr. Scott Bardo Mathieu Chabert Phone: +44 20 32077869 Phone: +33 170 365745 Deutsche Bank DZ Bank Gunnar Romer Sven Kürten Phone : +49 69 91031917 Phone : +49 69 744792072 HSBC Trinkaus & Burkhardt Kepler Cheuvreux Jan Keppeler Oliver Reinberg Pho

  31. Slide 31: Financial Calendar 2015 / 2016

    FINANCIAL CALENDAR 2015 / 2016 01/11-12/2016 The Trout Group's Annual 1x1 Management Access Event, San Francisco, USA 01/19/2016 14th German Corporate Conference, Frankfurt, GER 03/01-02/2016 Morgan Stanley European MedTech & Services Conference, London, UK 03/31/2016 Oddo Biotech / Medtech Day Foru

Stratec — Investor Presentation (January 2016) on 6ix